[go: up one dir, main page]

AR114930A1 - Composición farmacéutica - Google Patents

Composición farmacéutica

Info

Publication number
AR114930A1
AR114930A1 ARP180102544A ARP180102544A AR114930A1 AR 114930 A1 AR114930 A1 AR 114930A1 AR P180102544 A ARP180102544 A AR P180102544A AR P180102544 A ARP180102544 A AR P180102544A AR 114930 A1 AR114930 A1 AR 114930A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
fxr
oral administration
salt
farnesoid
Prior art date
Application number
ARP180102544A
Other languages
English (en)
Inventor
Geoffrey Gogniat
Sonali Bose
Claus Dieter Bischoff
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR114930A1 publication Critical patent/AR114930A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a una composición farmacéutica para administración oral que comprende un agonista no biliar del receptor farnesoide X (FXR) de ácido 2-[(1R,3R,5S)-3-({5-ciclopropil-3-[2-(trifluorometoxi)fenil]-1,2-oxazol-4-il}metoxi)-8-azabiciclo[3.2.1]octan-8-il]-4-fluoro-1,3-benzotiazol-6-carboxílico, o una sal farmacéuticamente aceptable sal del mismo, y al menos un excipiente lipídico; a una cápsula para administración oral que comprende dicha composición farmacéutica; al uso de dicha composición farmacéutica para el tratamiento de un trastorno o condición mediado por FXR; y a un procedimiento para preparar dicha composición farmacéutica.
ARP180102544A 2017-09-12 2018-09-07 Composición farmacéutica AR114930A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762557298P 2017-09-12 2017-09-12

Publications (1)

Publication Number Publication Date
AR114930A1 true AR114930A1 (es) 2020-11-11

Family

ID=63686041

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102544A AR114930A1 (es) 2017-09-12 2018-09-07 Composición farmacéutica

Country Status (15)

Country Link
US (2) US11207313B2 (es)
EP (1) EP3681485A1 (es)
JP (1) JP2020533297A (es)
KR (1) KR20200052280A (es)
CN (1) CN111093637A (es)
AR (1) AR114930A1 (es)
AU (1) AU2018332191B2 (es)
BR (1) BR112020004663A2 (es)
CA (1) CA3072559A1 (es)
CL (1) CL2020000601A1 (es)
IL (1) IL272419A (es)
MX (1) MX2020002432A (es)
RU (1) RU2020111980A (es)
TW (1) TW201919626A (es)
WO (1) WO2019053581A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018376904B2 (en) * 2017-11-30 2021-07-22 Novartis Ag FXR agonists for the treatment of liver diseases
CN114728955A (zh) * 2019-11-29 2022-07-08 广东东阳光药业有限公司 Tropifexor的新晶型及其制备方法
WO2021104022A1 (zh) * 2019-11-29 2021-06-03 广东东阳光药业有限公司 Tropifexor的新晶型及其制备方法
WO2021233461A1 (zh) * 2020-05-22 2021-11-25 苏州晶云药物科技股份有限公司 苯并噻唑类化合物的新晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
WO2007081773A2 (en) * 2006-01-05 2007-07-19 Reliant Pharmaceuticals, Inc Treatment of fatty liver
CA2779736A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
RU2743075C2 (ru) 2016-02-22 2021-02-15 Новартис Аг Способы применения агонистов fxr
AU2017223148B2 (en) 2016-02-22 2019-07-18 Novartis Ag Methods for using FXR agonists
EP3842043A1 (en) 2016-02-22 2021-06-30 Novartis AG Methods for using fxr agonists
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
EP4424364A3 (en) 2017-03-28 2024-11-27 Gilead Sciences, Inc. Methods of treating liver disease

Also Published As

Publication number Publication date
AU2018332191A1 (en) 2020-02-20
WO2019053581A1 (en) 2019-03-21
BR112020004663A2 (pt) 2020-09-15
US20190076418A1 (en) 2019-03-14
TW201919626A (zh) 2019-06-01
IL272419A (en) 2020-03-31
CN111093637A (zh) 2020-05-01
CA3072559A1 (en) 2019-03-21
US11207313B2 (en) 2021-12-28
CL2020000601A1 (es) 2020-09-11
RU2020111980A3 (es) 2021-11-23
RU2020111980A (ru) 2021-10-13
KR20200052280A (ko) 2020-05-14
US20220071983A1 (en) 2022-03-10
EP3681485A1 (en) 2020-07-22
JP2020533297A (ja) 2020-11-19
MX2020002432A (es) 2020-07-13
AU2018332191B2 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
AR114930A1 (es) Composición farmacéutica
CO2019007711A2 (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
NI201600098A (es) Composiciones farmacéuticas que comprenden azd9291
CL2008003789A1 (es) Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer.
SV2009002857A (es) Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
MX2020013116A (es) Sales y cristales novedosos.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
AR117814A1 (es) Compuestos moduladores de fxr (nr1h4)
JP2017505293A5 (es)
NI201800071A (es) Compuestos de isoindol
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
UY36124A (es) Derivados de carboxamida
CO6430439A2 (es) Agonistas del receptor de esfingosina -1- fosfato
CL2021001629A1 (es) Compuestos de halo-alilamina y uso de los mismos
AR109809A1 (es) Métodos para el uso de agonistas de fxr
UY36123A (es) Derivados de carboxamida
AR109652A1 (es) Métodos para utilizar agonistas de fxr
ECSP099602A (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
MX2017016862A (es) Composicion farmaceutica estable para administracion oral.
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure